Questions & explanations
1. Compare the roles of ATRX mutation and TERT promoter mutation in gliomas.
ATRX mutation and TERT promoter mutation are two different ways that gliomas maintain their telomeres. ATRX mutation leads to ALT, while TERT promoter mutation turns on telomerase. These two changes almost never happen in the same tumor. Gliomas with ATRX mutation are usually IDH-mutant astrocytomas, which grow more slowly. Gliomas with TERT promoter mutation are often glioblastomas or oligodendrogliomas, which are more aggressive. So the presence of one or the other helps classify the glioma type. For example, a tumor with IDH mutation and ATRX loss is likely an astrocytoma, while one with IDH mutation and TERT mutation is likely an oligodendroglioma.
2. How should a doctor handle a situation where a teenager refuses a life-saving brain surgery?
This is a difficult ethical problem. The doctor should first talk with the teenager to understand their fears or reasons, and provide clear information about the risks of not having surgery. The parents' wishes also matter, but the teenager's opinion is important because they are old enough to have some decision-making capacity. If the refusal continues, the hospital ethics committee may get involved to balance the teenager's autonomy with the need to save their life. In some cases, courts may decide if the treatment can be given against the teenager's will. The goal is to find a solution that respects the patient while ensuring their well-being.
3. Compare DBS with another treatment for Parkinson's, such as medication adjustments.
Medication adjustments can improve symptoms but often cause side effects like dyskinesias or 'on-off' fluctuations over time. DBS provides more stable symptom control by directly modulating brain circuits. Unlike medications, DBS does not cause nausea or confusion in most patients. However, DBS requires brain surgery, which carries risks like infection or bleeding. Medications are easier to adjust and can be changed quickly, while DBS settings need programming sessions. DBS is usually considered when medications are no longer effective enough. Both treatments are complementary; many patients still need lower doses of medication after DBS.
4. What evidence supports the use of DBS for Parkinson's disease?
Large clinical trials show that DBS improves motor function and quality of life more than medication alone. Studies report an average 40-60% improvement in motor scores on the Unified Parkinson's Disease Rating Scale (UPDRS). DBS also reduces medication-related side effects like dyskinesias and 'off' time. Long-term studies show benefits lasting at least 5-10 years. The evidence is strongest for patients with advanced Parkinson's who have motor fluctuations and dyskinesias. However, DBS does not stop disease progression or treat non-motor symptoms like dementia. Overall, it is a well-established therapy with high-level evidence.
5. Which patients with dystonia are most likely to benefit from DBS?
Patients with primary (inherited or idiopathic) dystonia, especially those with DYT1 gene mutation, often have excellent outcomes. Those with generalized dystonia affecting multiple body parts tend to benefit more than those with focal dystonia. Patients with cervical dystonia (torticollis) also respond well. Good candidates have disabling symptoms despite medication and botulinum toxin injections. They should have no significant cognitive impairment or psychiatric illness. Younger patients and those with shorter disease duration typically have better results. A thorough evaluation by a movement disorder specialist is essential.
6. Compare the effects of a hypothalamic versus a pituitary tumor on hormone production in children.
A hypothalamic tumor disrupts signals from the hypothalamus, so the pituitary may not receive proper instructions. This can cause low or high hormone release, depending on the tumor type. A pituitary tumor directly damages the pituitary cells, causing hormone excess or deficiency. For example, a hypothalamic tumor may cause low growth hormone due to lack of signal, while a pituitary tumor may cause high growth hormone (gigantism). Both need careful hormone testing and imaging to tell them apart. Treatment differs: hypothalamic tumors may need surgery or radiation, while pituitary tumors may be removed or treated with medicines.
7. Give an example of how DBS improves daily life for a Parkinson's patient.
A patient who has severe tremors and cannot hold a cup steady may find that after DBS, the tremor is greatly reduced. They can now drink without spilling and eat with a spoon. Another patient with medication-induced dyskinesias may have constant jerking movements that interfere with walking. After GPi DBS, these movements decrease, allowing them to walk more smoothly. DBS can also reduce the time when medications are not working, called 'off' periods. This means the patient can move more freely throughout the day. Overall, DBS helps patients perform daily activities like dressing, writing, and walking with less difficulty.
8. How is the VNS device programmed?
The device is programmed by a doctor using a handheld computer that communicates wirelessly. Settings include output current (how strong the stimulation is), frequency, pulse width, and on/off timing. Typical settings are 0.25-3.5 mA, 20-30 Hz, and 250-500 microseconds pulse width. The device cycles on for 30 seconds and off for 5 minutes, but this can be adjusted. Patients can also activate extra stimulation by swiping a magnet over the device when they feel a seizure coming. Programming is done in the clinic and may need adjustments over time. Side effects like hoarseness or cough can be reduced by lowering settings.
9. Compare the outcomes of spina bifida treatment in high-income vs low-income countries.
In high-income countries, most children with spina bifida get surgery soon after birth and have good long-term care, including physical therapy and bladder management. Many can walk with help and attend school. In low-income countries, many babies do not get surgery because there is no neurosurgeon or the family cannot pay. Those who survive may have severe disabilities, infections, or kidney failure. For example, a child in a rich country might have a normal life, while a child in a poor country might be bedridden and die young. Global efforts aim to close this gap by training surgeons and providing affordable care.
10. How does DBS for epilepsy compare to vagus nerve stimulation (VNS)?
Both DBS and VNS are neuromodulation therapies for drug-resistant epilepsy. DBS targets deep brain structures directly, while VNS stimulates the vagus nerve in the neck. DBS may be more effective for certain seizure types, especially focal seizures. VNS is less invasive because it does not require brain surgery. DBS allows more precise targeting but carries higher surgical risks like infection or bleeding. VNS has fewer cognitive side effects but can cause voice hoarseness or cough. The choice depends on the seizure type, patient preference, and medical team expertise. Both can be effective when medications fail.
11. What outcomes can patients expect from VNS for epilepsy?
VNS reduces seizure frequency by about 30-50% on average after one year. Some patients become seizure-free, though this is less common. The benefit often increases over time, with some studies showing better results after 2-3 years. VNS can also shorten seizure duration and improve recovery after a seizure. It may improve mood and quality of life even without seizure reduction. However, VNS is not a cure; most patients still need to take medication. Side effects like voice changes, cough, or shortness of breath are common but usually mild. Overall, VNS is a safe and effective option for drug-resistant epilepsy.
12. Compare the roles of TP53 mutation and RB1 loss in glioblastoma.
TP53 mutation and RB1 loss both contribute to glioblastoma but affect different checkpoints. TP53 mutation allows cells with DNA damage to survive and divide, leading to more mutations. RB1 loss removes the G1/S checkpoint, letting cells enter the cell cycle freely. In glioblastoma, TP53 mutation is more common in secondary glioblastomas that arise from lower-grade gliomas. RB1 loss is more common in primary glioblastomas that appear suddenly. Both are associated with poor prognosis, but they often occur together with other changes. Understanding which pathway is altered helps in choosing targeted therapies.